Abstract
RAC1 P29 is the third most commonly mutated codon in human cutaneous melanoma, after BRAF V600 and NRAS Q61. Here, we study the role of RAC1P29S in melanoma development and reveal that RAC1P29S activates PAK, AKT, and a gene expression program initiated by the SRF/MRTF transcriptional pathway, which results in a melanocytic to mesenchymal phenotypic switch. Mice with ubiquitous expression of RAC1P29S from the endogenous locus develop lymphoma. When expressed only in melanocytes, RAC1P29S cooperates with oncogenic BRAF or with NF1-loss to promote tumorigenesis. RAC1P29S also drives resistance to BRAF inhibitors, which is reversed by SRF/MRTF inhibitors. These findings establish RAC1P29S as a promoter of melanoma initiation and mediator of therapy resistance, while identifying SRF/MRTF as a potential therapeutic target.
Original language | English |
---|---|
Pages (from-to) | 68-83.e9 |
Journal | Cancer cell |
Volume | 36 |
Issue number | 1 |
DOIs | |
Publication status | Published - 8 Jul 2019 |
Keywords
- Alleles
- Amino Acid Substitution
- Animals
- Cell Line, Tumor
- Cell Survival/drug effects
- Cell Transformation, Neoplastic/genetics
- Disease Models, Animal
- Drug Resistance, Neoplasm/genetics
- Epithelial-Mesenchymal Transition/genetics
- Female
- Gene Expression
- Humans
- Male
- Melanocytes/metabolism
- Melanoma/etiology
- Mice
- Mice, Transgenic
- Models, Biological
- Mutation
- Prognosis
- Protein Kinase Inhibitors/pharmacology
- Proto-Oncogene Proteins B-raf/genetics
- Serum Response Factor
- Xenograft Model Antitumor Assays
- rac1 GTP-Binding Protein/genetics